One study evaluates the safety of autologous CAR T cells targeting HER2 in subjects with progressive recurrent or refractory HER2‐positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS after standard care interventions (NCT02442297). This evidence concerns the gene ERBB2 and central nervous system neoplasm.